Neuroprotective effects of PPAR‐γ agonist rosiglitazone in N171‐82Q mouse model of Huntington's disease
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Huntington's disease (HD) is a devastating genetic neurodegenerative disease caused by CAG trinucleotide expansion in the exon‐1 region of the huntingtin gene. Currently, no cure is available. It is becoming increasingly apparent that mutant Huntingtin (HTT) impairs metabolic homeostasis and causes transcriptional dysregulation. The peroxisome proliferator‐activated receptor gamma (PPAR‐γ) is a transcriptional factor that plays a key role in regulating genes involved in energy metabolism; recent studies demonstrated that PPAR‐γ activation prevented mitochondrial depolarization in cells expressing mutant HTT and attenuated neurodegeneration in various models of neurodegenerative diseases. PPAR‐γ‐coactivator 1α (PGC‐1 α) transcription activity is also impaired by mutant HTT. We now report that the PPAR‐γ agonist, rosiglitazone (RSG), significantly attenuated mutant HTT‐induced toxicity in striatal cells and that the protective effect of RSG is mediated by activation of PPAR‐γ. Moreover, chronic administration of RSG (10 mg/kg/day, i.p) significantly improved motor function and attenuated hyperglycemia in N171‐82Q HD mice. RSG administration rescued brain derived neurotrophic factor(BDNF) deficiency in the cerebral cortex, and prevented loss of orexin‐A‐immunopositive neurons in the hypothalamus of N171‐82Q HD mice. RSG also prevented PGC‐1α reduction and increased Sirt6 protein levels in HD mouse brain. Our results suggest that modifying the PPAR‐γ pathway plays a beneficial role in rescuing motor function as well as glucose metabolic abnormalities in HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
Cantó, C., & Auwerx, J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328328d0a4 · Cited by 1,624
Defects in Adaptive Energy Metabolism with CNS-Linked Hyperactivity in PGC-1α Null Mice
Lin, J., Wu, P.-H., Tarr, P. T., Lindenberg, K. S., St-Pierre, J., Zhang, C.-Y., Mootha, V. K., Jäger, S., Vianna, C. R., Reznick, R. M., et al. (2004) · Cell · doi:10.1016/j.cell.2004.09.013 · Cited by 1,162
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience · doi:10.1038/nn884 · Cited by 1,030
Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006) · Cell · doi:10.1016/j.cell.2006.09.015 · Cited by 1,012
The Histone Deacetylase Sirt6 Regulates Glucose Homeostasis via Hif1α
Zhong, L., D'Urso, A., Toiber, D., Sebastian, C., Henry, R. E., Vadysirisack, D. D., Guimaraes, A., Marinelli, B., Wikstrom, J. D., Nir, T., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.041 · Cited by 1,001
Weydt, P., Pineda, V. V., Torrence, A. E., Libby, R. T., Satterfield, T. F., Lazarowski, E. R., Gilbert, M. L., Morton, G. J., Bammler, T. K., Strand, A. D., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.004 · Cited by 562
PGC-1α regulates the mitochondrial antioxidant defense system in vascular endothelial cells
VALLE, I., ALVAREZBARRIENTOS, A., ARZA, E., LAMAS, S., & MONSALVE, M. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.01.026 · Cited by 556 · cited 1×
“PPAR-c coactivator PGC-1a interacts with a number of transcriptional factors, and regulates genes involved in mitochondrial respiration (Valle et al. 2005; Liang and Ward 2006; McGill and Beal 2006; Rasbach and Schnellmann 2007; Zheng et al. 2010).”
BackgroundDuan, W., Guo, Z., Jiang, H., Ware, M., Li, X.-J., & Mattson, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536856100 · Cited by 428 · cited 4×
“BDNF deficiency occurs commonly in HD patients as well as in HD mouse models, including N171-82Q HD mice (Duan et al. 2003).”
BackgroundMethodInfluentialSelf-citationBaquet, Z. C., Gorski, J. A., & Jones, K. R. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3920-03.2004 · Cited by 414
BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice
Xie, Y., Hayden, M. R., & Xu, B. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1637-10.2010 · Cited by 236 · cited 4×
“dysregulation, mitochondrial dysfunction, increased oxidative stress, excitotoxicity, and neurotrophic factor deficiency have been implicated in HD pathogenesis (Panov et al. 2002; Cui et al. 2006; Bithell et al. 2009; Giralt et al. 2009; Rosenstock et al. 2010; Xie et al. 2010; Ross and Tabrizi 2011; Zuccato et al. 2…”
BackgroundInfluential
Cited by
ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
Doll, S., Proneth, B., Tyurina, Y. Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2239 · Cited by 4,293
PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease
Corona, J. C., & Duchen, M. R. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.06.023 · Cited by 259
Localization of PPAR isotypes in the adult mouse and human brain
Warden, A., Truitt, J., Merriman, M., Ponomareva, O., Jameson, K., Ferguson, L. B., Mayfield, R. D., & Harris, R. A. (2016) · Scientific Reports · doi:10.1038/srep27618 · Cited by 242
Jamwal, S., Blackburn, J. K., & Elsworth, J. D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107705 · Cited by 236
“rosiglitazone considerably improved motor function, increased BDNF levels in cerebral cortex, prevented degeneration of orexin-A-immunopositive neurons in the hypothalamus, averted PGC1α reduction and increased Sirt6 protein levels (Jin et al., 2013).”
BackgroundClinical Features of Huntington’s Disease
Ghosh, R., & Tabrizi, S. J. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-71779-1_1 · Cited by 202
Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models
Komen, J. C., & Thorburn, D. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12413 · Cited by 149
“TZDs have also been tested successfully on multiple models of HD recently (Chiang et al., 2010; Napolitano et al., 2011; Jin et al., 2013).”
BackgroundValdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., Muñoz, E., & Sagredo, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0304-z · Cited by 143
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63233-3.00017-8 · Cited by 122
Neuroinflammation in Huntington’s Disease: A Starring Role for Astrocyte and Microglia
Saba, J., Couselo, F. L., Bruno, J., Carniglia, L., Durand, D., Lasaga, M., & Caruso, C. (2022) · Current Neuropharmacology · doi:10.2174/1570159x19666211201094608 · Cited by 117
“Expression of the transcription factor PGC-1α, which regulates mitochondrial biogenesis, is reduced in HD models [187, 188], though it is not known whether this factor is also diminished in astrocytes.”
Nuclear receptors in neurodegenerative diseases
Skerrett, R., Malm, T., & Landreth, G. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.019 · Cited by 94
Zuo, Y., Huang, L., Enkhjargal, B., Xu, W., Umut, O., Travis, Z. D., Zhang, G., Tang, J., Liu, F., & Zhang, J. H. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1432-5 · Cited by 88
Unveiling ferroptosis as a promising therapeutic avenue for colorectal cancer and colitis treatment
Kao, A. T., Cabanlong, C. V., Padilla, K., & Xue, X. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.025 · Cited by 30
Metadata
- Authors
- Jin, J., Albertz, J., Guo, Z., Peng, Q., Rudow, G., Troncoso, J. C., Ross, C. A., & Duan, W.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2013-03-05
- Volume
- 125
- Issue
- 3
- Pages
- 410-419
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2008582944
- Cited by
- 119
- References
- 13
- FWCI
- 5.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.